COVID-19-related trial delays, lower orders and impact on business performance
First written in FY2020. 7 of 14 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.
6 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「Although the number of infections is currently under control and the impact on economic activity is limited, if infections were to spread again, this could disrupt the business activities of the Group and its customers and have a significant impact on the Group's performance.」
It was explained that the number of infections is under control and the impact on economic activity is limited, indicating that the previous impact of the infectious disease has diminished. At the same time, the risk of an impact on performance if infections spread again continues to be explicitly disclosed. - FY2024-Q2RestatedAnnual report
「During the six-month period ended the second quarter, there were no new business or other risks, nor any significant changes to the business or other risks described in the securities report for the previous fiscal year.」
It reconfirms that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2024-Q1RestatedAnnual report
「During the first 3 months of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It reconfirms that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended the third quarter, there were no new business or other risks, nor any significant changes to the business or other risks described in the securities report for the previous fiscal year.」
It explicitly states that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2023-Q2RestatedAnnual report
「During the six-month period ended the second quarter, there were no new business or other risks, nor any significant changes to the business or other risks described in the securities report for the previous fiscal year.」
It states that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2023-Q1RestatedAnnual report
「During the first 3 months of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It states that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2022-Q3MitigatedAnnual report
「Although the number of tests remained high through the second quarter of the consolidated fiscal period, both the number of infections and the number of tests declined during the third quarter, and the impact on performance became limited.」
The impact of the sharp increase in testing related to the infectious disease declined during the third quarter, and the impact on performance was described as limited. - FY2022-Q2RestatedAnnual report
「During the six-month period ended the second quarter, there were no new business or other risks, nor any significant changes to the business or other risks described in the securities report for the previous fiscal year.」
It states that there have been no new occurrences or significant changes in business and other risks, including COVID-19. - FY2022-Q1RestatedAnnual report
「During the first 3 months of the current fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
This quarterly report explicitly states that there have been no new risks or significant changes to existing risks. Although the body of the report describes responses to a resurgence of infections and variant strains, these are not treated as significant changes for risk disclosure purposes. - FY2021WorsenedAnnual report
「There is currently no clear prospect of the COVID-19 situation converging, but if its impact continues for an extended period, the company’s performance may be materially affected by an extreme slowdown in corporate activity, an increase in corporate bankruptcies and an extreme decline in consumption.」
Although business activity recovered, there was no clear prospect of the infectious disease situation converging, and the company specified that the risk could extend to a prolonged slowdown in corporate activity, an increase in bankruptcies and weak consumption. - FY2021-Q3MitigatedAnnual report
「During the first 9 months of the current fiscal year, the company was forced to reduce order activity for nonclinical and clinical studies for a certain period due to the spread of COVID-19. However, as sales activities conducted during the pandemic, centered on web meetings and similar methods, became established, new orders recovered steadily from the second quarter onward.」
Regarding the decline in order activity for clinical and nonclinical studies caused by the infectious disease, the company stated that new orders recovered steadily from the second quarter onward as web meetings and other sales activities became established. - FY2021-Q2MitigatedAnnual report
「In the second quarter, postponed studies resumed, and new orders also gradually began to recover.」
Regarding the impact of COVID-19 on trial postponements and lower orders, the company stated that trial postponements had been resolved and new orders were recovering, indicating that the impact had eased to some extent. It did not state that the threat from the infectious disease itself had been resolved. - FY2021-Q1MaterialisedAnnual report
「The spread of COVID-19 restricted imports of animals used for outsourced nonclinical studies and affected operations, including by preventing nonclinical studies from progressing as planned. In the clinical business, conditions also arose that made subject recruitment and the conduct of trials difficult.」
Regarding the infectious disease risk described in the previous fiscal year, the company stated that restrictions on animal imports, delays in nonclinical studies and difficulties conducting clinical trials had actually occurred during the current quarter. - FY2020First statedAnnual report
「However, in the CRO business, the company currently has no clear prospect of resuming imports of some animals used for outsourced nonclinical studies, and has had to suspend recruitment of subjects for clinical trials, raising concerns that orders for some types of studies may decline.」
COVID-19 was identified as a major risk for the first time, with the company stating that suspension of animal imports, suspension of subject recruitment, trial delays and lower order activity had already occurred.